JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES.

• 1. 用于治疗骨髓增生异常综合征的JAK1抑制剂 [P] . 中国专利： CN112494652A . 2021-03-16
• 2. 用于治疗骨髓增生异常综合征的JAK1抑制剂 [P] . 中国专利： CN106456773A . 2017-02-22
• 3. JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES. [P] . MX2016011103A . 2017-02-28

  机译： JAK1抑制剂，用于治疗骨髓增生异常综合征。

• 4. JAK1 JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES [P] . 韩国专利： KR20160136323A . 2016-11-29

  机译： JAK1 JAK1抑制剂用于治疗骨髓增生异常综合征

• 5. JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES [P] . US2021069193A1 . 2021-03-11

  机译： JAK1抑制剂治疗骨髓增强症综合征

• 1. Yu Gan Long Ameliorates Hepatic Fibrosis by Inhibiting PI3K/AKT,Ras/ERK and JAK1/STAT3 Signaling Pathways in CCl4-induced Liver Fibrosis Rats [J] . Hou-gang LI, Peng-tao YOU, Yu XI, 当代医学科学(英文) . 2020,第003期
• 2. miR-4651 inhibits cell proliferation of gingival mesenchymal stem cells by inhibiting HMGA2 under nifedipine treatment [J] . Xiao Han, Ruzhuang Yang, Haoqing Yang, 国际口腔科学杂志（英文版） . 2020,第002期
• 3. DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. [J] . Griffiths EA, Gore SD Seminars in Hematology . 2008,第1期
• 4. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid (SAHA)) in patients with advanced leukemias and myelodysplastic syndromes. [J] . Garcia-Manero G, Yang H, Bueso-Ramos C, Blood: The Journal of the American Society of Hematology . 2008,第3期
• 5. Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes. [J] . Cortes J, Faderl S, Estey E, Journal of Clinical Oncology . 2005,第12期
• 6. Computational analyses of JAK1 kinase domain: Subtle changes in the catalytic cleft influence inhibitor specificity [C] . Xiaonan Zhang, Yunwen Hu, Zhenghong Yuan 第四届国际分子模拟与信息技术应用学术会议（The 4th International Conference of Molecular Simulations and Applied Informatics Technologies）论文集 . 2008
• 7. Inhibition of protein kinase C restores morphine efficacy following excitotoxic spinal cord injury: Implications for the treatment of post-spinal cord injury pain syndromes. [D] . Nolan, Todd Andrew. 2008
• 8. Treatment options for lower-risk myelodysplastic syndromes. Where are we now? [O] . Virginia O. Volpe, Rami S. Komrokji 2021
• 9. PROSPECTIVE PHASE II STUDY ON 5-days AZACITIDINE (5d-AZA) FOR TREATMENT OF SYMPTOMATIC AND/OR ERYTHROPOIETIN UNRESPONSIVE PATIENTS WITH LOW/INT-1 RISK MYELODYSPLASTIC SYNDROMES. [O] . Filì C, Malagola M, Follo MY, 2013
• 10. Role of mDia1 in the Aberrant Innate Immune Signaling in del(5q) Myelodysplastic Syndromes. [R] . Ji, P. 2017

• 1. Exploration of the molecular mechanism of Indigo Naturalis in the treatment of myelodysplastic syndromes through integrated pharmacological study [J] . Qin-Shuai Zhang ,Li-Li Sha ,Hao Zhang . TMR理论与假说 . 2021,第003期
• 2. miR-4651 inhibits cell proliferation of gingival mesenchymal stem cells by inhibiting HMGA2 under nifedipine treatment [J] . Xiao Han ,Ruzhuang Yang ,Haoqing Yang . 国际口腔科学杂志 . 2020,第002期
• 3. Long-Term Monoacylglycerol Lipase Inhibitor Treatment Decelerates Pathological Changes in APP/PS1-21 Mice, but Behavioral Improvements Require Early-Stage Treatment Onset—Short Report [J] . Rea Pihlaja ,Noora Lindgren ,Annamari Torittu . 神经科学国际期刊（英文） . 2018,第2期
• 4. 应用DNA甲基转移酶抑制剂治疗骨髓增生异常综合征的新方法 [C] . 惠吴函 . 第53届美国血液年会 . 2012
• 5. JAK1/JAK2抑制剂Momelotinib软膏的制备及其对特应性皮炎模型小鼠的治疗作用和机制研究 [A] . 金文玉 . 2019